New Delhi, May 14 -- Roche Pharma India has launched Tecentriq SC (atezolizumab), the country's first subcutaneous, or under-the-skin, immunotherapy for lung cancer, the company said on Thursday. This breakthrough formulation marks a significant shift in oncology care, reducing treatment administration time from several hours of conventional intravenous (IV) infusion to just seven minutes.

Approved by the Drugs Controller General of India (DCGI) around two months ago for adjuvant and metastatic non-small cell lung cancer (NSCLC), Tecentriq SC is now available across India with more than 100 patients already on immunotherapy.

The launch comes at a time when India grapples with a rising cancer burden. Lung cancer remains a leading cause o...